ImmunoPrecise Antibodies Ltd.
IPA
$3.20
$0.5721.67%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.57M | 17.42M | 17.70M | 17.74M | 18.16M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.57M | 17.42M | 17.70M | 17.74M | 18.16M |
| Cost of Revenue | 7.88M | 8.57M | 8.80M | 9.19M | 9.23M |
| Gross Profit | 9.69M | 8.85M | 8.90M | 8.55M | 8.93M |
| SG&A Expenses | 13.48M | 13.85M | 13.98M | 13.79M | 14.15M |
| Depreciation & Amortization | 1.40M | 1.85M | 1.93M | 2.01M | 2.20M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.32M | 27.99M | 28.43M | 28.47M | 28.58M |
| Operating Income | -8.75M | -10.57M | -10.73M | -10.73M | -10.42M |
| Income Before Tax | -24.33M | -36.86M | -22.16M | -21.83M | -21.21M |
| Income Tax Expenses | -2.87M | -3.95M | -2.41M | -2.17M | -1.92M |
| Earnings from Continuing Operations | -21.45 | -32.91 | -19.75 | -19.66 | -19.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.45M | -32.91M | -19.75M | -19.66M | -19.30M |
| EBIT | -8.75M | -10.57M | -10.73M | -10.73M | -10.42M |
| EBITDA | -6.54M | -7.97M | -7.78M | -7.45M | -6.67M |
| EPS Basic | -0.67 | -1.12 | -0.74 | -0.74 | -0.74 |
| Normalized Basic EPS | -0.19 | -0.24 | -0.26 | -0.26 | -0.25 |
| EPS Diluted | -0.67 | -1.12 | -0.74 | -0.74 | -0.74 |
| Normalized Diluted EPS | -0.19 | -0.24 | -0.26 | -0.26 | -0.25 |
| Average Basic Shares Outstanding | 133.92M | 114.76M | 107.71M | 104.63M | 102.55M |
| Average Diluted Shares Outstanding | 133.92M | 114.76M | 107.71M | 104.63M | 102.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |